Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study
Open Forum Infectious Diseases · 28.03.2024 · 11 (4)
DOI: 10.1093/ofid/ofae160 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 18.03.2024. Verfasst von Marta Vasylyev und 25 weiteren Autor:innen. Beteiligte Einrichtung: Section of Infectious Diseases, Department of Internal Medicine, and Department of Medical Microbiology and Infectious Diseases, Erasmus University M…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare, Dutch Ministry of Health, Welfare and Sport, Infectious Disease Control of the National Institute for Public Health and the Environment.
Abstract (Originalsprache)
Background
Confirming the efficacy of dolutegravir/lamivudine in clinical practice solidifies recommendations on its use.
Methods
Prospective cohort study (DUALING) in 24 human immunodeficiency virus (HIV) treatment centers in the Netherlands. HIV RNA–suppressed cases were on triple-drug antiretroviral regimens without prior virological failure or resistance and started dolutegravir/lamivudine. Cases were 1:2 matched to controls on triple-drug antiretroviral regimens by the use of dolutegravir-based regimens, age, sex, transmission route, CD4+ T-cell nadir, and HIV RNA zenith. The primary endpoint was the treatment failure rate in cases versus controls at 1 year by intention-to-treat and on-treatment analyses with 5% noninferiority margin.
Results
The 2040 participants were 680 cases and 1380 controls. Treatment failure in the 390 dolutegravir-based cases versus controls occurred in 8.72% and 12.50% (difference: −3.78% [95% confidence interval {CI}, −7.49% to .08%]) by intention-to-treat and 1.39% and 0.80% (difference: 0.59% [95% CI, –.80% to 1.98%]) by on-treatment analyses. The treatment failure risk in 290 non-dolutegravir-based cases was also noninferior to controls. Antiretroviral regimen modifications unrelated to virological failure explained the higher treatment failure rate by intention-to-treat. A shorter time on triple-drug antiretroviral therapy and being of non-Western origin was associated with treatment failure. Treatment failure, defined as 2 consecutive HIV RNA >50 copies/mL, occurred in 4 cases and 5 controls but without genotypic resistance detected. Viral blips occured comparable in cases and controls but cases gained more weight, especially when tenofovir-based regimens were discontinued.
Conclusions
In routine care, dolutegravir/lamivudine was noninferior to continuing triple-drug antiretroviral regimens after 1 year, supporting the use of dolutegravir/lamivudine in clinical practice. Clinical Trials Registration NCT04707326.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Infectious Diseases, Department of Internal Medicine, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Stichting HIV Monitoring, Amsterdam, The Netherlands.
- Department of Internal Medicine, Spaarne Gasthuis, Haarlem/Hoofddorp, The Netherlands.
- Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands.
- Department of Internal Medicine, Catharina Ziekenhuis Eindhoven, Eindhoven, The Netherlands.
- Department of Internal Medicine, Elisabeth Tweesteden Ziekenhuis, Tilburg, The Netherlands.
ORCID-Profile: Marta Vasylyev, Casper Rokx
Förderung
- ViiV Healthcare
- Dutch Ministry of Health, Welfare and Sport
- Infectious Disease Control of the National Institute for Public Health and the Environment
Zitieren
APA
Vasylyev, M., Wit, F. W. N. M., Jordans, C. C. E., Soetekouw, R., van Lelyveld, S. F. L., Kootstra, G. J., Delsing, C. E., Ammerlaan, H. S. M., van Kasteren, M. E. E., Brouwer, A. E., Leyten, E. M. S., Claassen, M. A. A., Hassing, R. J., den Hollander, J. G., van den Berge, M., Roukens, A. H. E., Bierman, W. F. W., Groeneveld, P. H. P., Lowe, S. H., …, & Rokx, C. (2024). Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study. Open Forum Infectious Diseases, 11(4). https://doi.org/10.1093/ofid/ofae160
Vancouver
Vasylyev M, Wit FWNM, Jordans CCE, Soetekouw R, van Lelyveld SFL, Kootstra GJ, et al. Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study. Open Forum Infectious Diseases. 2024;11(4). doi:10.1093/ofid/ofae160
BibTeX
@article{Vasylyev2024,
author = {Vasylyev, Marta and Wit, Ferdinand W N M and Jordans, Carlijn C E and Soetekouw, Robin and van Lelyveld, Steven F L and Kootstra, Gert-Jan and Delsing, Corine E and Ammerlaan, Heidi S M and van Kasteren, Marjo E E and Brouwer, Annemarie E and Leyten, Eliane M S and Claassen, Mark A A and Hassing, Robert-Jan and den Hollander, Jan G and van den Berge, Marcel and Roukens, Anna H E and Bierman, Wouter F W and Groeneveld, Paul H P and Lowe, Selwyn H and van Welzen, Berend J and Richel, Olivier and Nellen, Jeannine F and van den Berk, Guido E L and van der Valk, Marc and Rijnders, Bart J A and Rokx, Casper},
title = {Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study},
journal = {Open Forum Infectious Diseases},
year = {2024},
volume = {11},
number = {4},
doi = {10.1093/ofid/ofae160}
}
EUVIMED